DDInter380 DDInter1628
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Cimetidine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cimetidine {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Cimetidine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Cimetidine {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) interacts with {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cimetidine {u} (Compound) downregulates {v} (Gene) COTL1
COTL1 {u} (Gene) is regulated by {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Cimetidine {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) interacts with {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cimetidine {u} may lead to a major life threatening interaction when taken with {v} Epirubicin
Epirubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cimetidine {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is regulated by {v} (Gene) SMNDC1
SMNDC1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Cimetidine (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Ruxolitinib (Compound)
Cimetidine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Cimetidine (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) interacts with IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Cimetidine (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is regulated by JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Cimetidine (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) interacts with PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Cimetidine may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Cimetidine (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is regulated by SMNDC1 (Gene) and SMNDC1 (Gene) is upregulated by Ruxolitinib (Compound)